NCT05785156Recruiting

Diagnostic and Prognostic Value of New Quick Tests of Action Slowing in Stroke and in Cognitive Neurodegenerative Disease

Source: ClinicalTrials.gov · Last updated 13 May 2026

Brief summary (registry, in English)

A large series of recent studies have documented the frequency of the slowing of the action in brain diseases, especially vascular and neurodegenerative diseases. In stroke, the predictive value of action slowing at the acute phase for predicting post-stroke functional outcome remains poorly investigated. In neurodegenerative diseases, the diagnostic relevance of the slowing at the prodromal stage remains unknown and this diagnostic requires new tests. Finally, in terms of anatomical determinants, few studies have studied the determinants of action slowing. The objectives of this project are to Determine the diagnostic and prognostic value of action slowing assessed with new quick tests in patients with acute stroke (Neurovascular Unit) and cognitive neurodegenerative disorders (Alzheimer Disease (AD), Lewy Body disease (LBD), Fronto Temporal lobar degeneration (FTLD), Cortico Basal Degeneration (CBD) and Progressive Supra Nuclear Palsy (PSNP)) and to define the lesion determinants with VBM and VLSM

Status (registry): Recruiting
Study type: Observational
Enrollment: 129 (estimated)
First submitted: 14 Mar 2023
Start date: 16 Jul 2021
Primary completion date: 16 Jul 2027
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Diseases: Stroke, Alzheimer disease
NCT number: NCT05785156

What you commit to

Study type: Observational
Planned participants: 129
From 16 Jul 2021 to the primary completion date, 16 Jul 2027
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

Previously diagnosed dementia
epilepsy prior to stroke still requiring previous treatment
brain tumor or brain radiation therapy
treatment with gold salts, D Penicillamine or other treatment with cognitive effect

Other illness

Other current or past brain condition
Parkinson disease, multiple sclerosis...
Active or past psychiatric disorders requiring a stay\> 2 days in a specialized environment
Alcohol (\> 3 glasses / day) or history of alcohol withdrawal syndrome
opiate or cocaine addiction or opiate withdrawal syndrome
respiratory failure requiring oxygen therapy
heart failure (orthopnea\> 2 pillows)
cancer with paraneoplastic syndrome

Lab values

renal failure (dialysis or creatinine clearance \<30)
hepatic failure (spontaneous INR\> 1.5 or PT \<60%)

Other

Mental retardation or guardianship
severe head trauma
Current or past schizophrenia or psychosis
Contra indication to MRI
Comorbidity with life expectancy \<1 year
Comorbidity affecting cognition in particular:
persistent vigilance disturbances (NIHSS1a score ≤1)
Patient under guardianship or curators or private under public law
Pregnant and / or lactating wom

Who the study is looking for

Patients between 40 and 85 years old,
French native language,
Social Security affiliation.
University Memory Clinic for: Mild severity disorder (MMSE\> 19) or major severity disorder related to AD : Albert 2011 criteria ; McKhann 2011
to MCL according to McKeith criteria
to FTLD according to Rascovsky 2011 criteria
BBD according to Armstrong's criteria
related to PSP according to Höglinger criteria

Age in the registry: 40 years to 85 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
CHU Amiens Coordinator of this site? Confirm its status	Amiens	France	Recruiting

This page is information, not medical advice. Discuss any trial with your doctor.